ID

39010

Beschreibung

Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT01652729

Link

https://clinicaltrials.gov/show/NCT01652729

Stichworte

Versionen (1)
  1. 19.11.19 19.11.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

19. November 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Diabetes Type 2 NCT01652729

Englisch

Eligibility Diabetes Type 2 NCT01652729

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
at least 18 years old
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
diagnosed with type 2 diabetes mellitus
Beschreibung

Diabetes Mellitus, Non-Insulin-Dependent

Datentyp

boolean

Alias
UMLS CUI [1]
C0011860
hba1c of 7.1% to 11.0%, inclusive, at screening
Beschreibung

Hemoglobin A1c measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0474680
has stable body weight, i.e., not varying by >3% for at least 3 months prior to screening
Beschreibung

Stable body weight

Datentyp

boolean

Alias
UMLS CUI [1]
C0517386
fasting plasma glucose concentration <280 mg/dl (15.5 mmol/l) at screening
Beschreibung

Plasma fasting glucose measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0583513
body mass index of <45 kg/m2 at screening
Beschreibung

Body mass index

Datentyp

boolean

Alias
UMLS CUI [1]
C1305855
has been treated with a stable regimen of ≥1500 mg/day metformin for a minimum of 2 months prior to visit 1 (screening)
Beschreibung

Metformin Dose Stable U/day

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0025598
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [1,4]
C0456683
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of pancreatitis or triglycerides >=500 mg/dl
Beschreibung

Pancreatitis | Triglycerides measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0030305
UMLS CUI [2]
C0202236
medullary carcinoma or multiple endocrine neoplasia (men2) or a family history of either
Beschreibung

Medullary carcinoma of thyroid | Familial medullary thyroid carcinoma | Multiple Endocrine Neoplasia Type | Family history of multiple endocrine neoplasia Type

Datentyp

boolean

Alias
UMLS CUI [1]
C0238462
UMLS CUI [2]
C1833921
UMLS CUI [3,1]
C0027662
UMLS CUI [3,2]
C0332307
UMLS CUI [4,1]
C4039247
UMLS CUI [4,2]
C0332307
history of renal transplantation, or is currently receiving renal dialysis, or has an estimated creatinine clearance <50 ml/min
Beschreibung

Kidney Transplantation | Dialysis procedure | Estimated creatine clearance

Datentyp

boolean

Alias
UMLS CUI [1]
C0022671
UMLS CUI [2]
C0011946
UMLS CUI [3]
C1273051
active cardiovascular disease
Beschreibung

Cardiovascular Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0007222
presence or history of severe congestive heart failure
Beschreibung

Congestive heart failure Severe

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0018802
UMLS CUI [1,2]
C0205082
central nervous system disease, including epilepsy
Beschreibung

CNS disorder | Epilepsy

Datentyp

boolean

Alias
UMLS CUI [1]
C0007682
UMLS CUI [2]
C0014544
liver disease
Beschreibung

Liver disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0023895
history of severe gastrointestinal diseases
Beschreibung

Gastrointestinal Diseases Severe (

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0017178
UMLS CUI [1,2]
C0205082
clinically significant malignant disease
Beschreibung

Malignant disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0442867
repeated severe hypoglycemia within the last 6 months
Beschreibung

Hypoglycemia Severe Repeated

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020615
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0205341
any exposure to exenatide (byetta® or bydureon™) or any glp-1 analog
Beschreibung

Exposure to Exenatide | Exposure to Byetta | Exposure to Bydureon | Exposure to GLP-1 Analogue

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0167117
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C1636686
UMLS CUI [3,1]
C0332157
UMLS CUI [3,2]
C3257792
UMLS CUI [4,1]
C0332157
UMLS CUI [4,2]
C3273809
any dpp-4 inhibitor within 3 months prior screening
Beschreibung

Dipeptidyl Peptidase-4 Inhibitor

Datentyp

boolean

Alias
UMLS CUI [1]
C3537225
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Diabetes Type 2 NCT01652729

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
at least 18 years old
boolean
C0001779 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hba1c of 7.1% to 11.0%, inclusive, at screening
boolean
C0474680 (UMLS CUI [1])
Stable body weight
Item
has stable body weight, i.e., not varying by >3% for at least 3 months prior to screening
boolean
C0517386 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
fasting plasma glucose concentration <280 mg/dl (15.5 mmol/l) at screening
boolean
C0583513 (UMLS CUI [1])
Body mass index
Item
body mass index of <45 kg/m2 at screening
boolean
C1305855 (UMLS CUI [1])
Metformin Dose Stable U/day
Item
has been treated with a stable regimen of ≥1500 mg/day metformin for a minimum of 2 months prior to visit 1 (screening)
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0456683 (UMLS CUI [1,4])
Item Group
C0680251 (UMLS CUI)
Pancreatitis | Triglycerides measurement
Item
history of pancreatitis or triglycerides >=500 mg/dl
boolean
C0030305 (UMLS CUI [1])
C0202236 (UMLS CUI [2])
Medullary carcinoma of thyroid | Familial medullary thyroid carcinoma | Multiple Endocrine Neoplasia Type | Family history of multiple endocrine neoplasia Type
Item
medullary carcinoma or multiple endocrine neoplasia (men2) or a family history of either
boolean
C0238462 (UMLS CUI [1])
C1833921 (UMLS CUI [2])
C0027662 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C4039247 (UMLS CUI [4,1])
C0332307 (UMLS CUI [4,2])
Kidney Transplantation | Dialysis procedure | Estimated creatine clearance
Item
history of renal transplantation, or is currently receiving renal dialysis, or has an estimated creatinine clearance <50 ml/min
boolean
C0022671 (UMLS CUI [1])
C0011946 (UMLS CUI [2])
C1273051 (UMLS CUI [3])
Cardiovascular Disease
Item
active cardiovascular disease
boolean
C0007222 (UMLS CUI [1])
Congestive heart failure Severe
Item
presence or history of severe congestive heart failure
boolean
C0018802 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
CNS disorder | Epilepsy
Item
central nervous system disease, including epilepsy
boolean
C0007682 (UMLS CUI [1])
C0014544 (UMLS CUI [2])
Liver disease
Item
liver disease
boolean
C0023895 (UMLS CUI [1])
Gastrointestinal Diseases Severe (
Item
history of severe gastrointestinal diseases
boolean
C0017178 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
Malignant disease
Item
clinically significant malignant disease
boolean
C0442867 (UMLS CUI [1])
Hypoglycemia Severe Repeated
Item
repeated severe hypoglycemia within the last 6 months
boolean
C0020615 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205341 (UMLS CUI [1,3])
Exposure to Exenatide | Exposure to Byetta | Exposure to Bydureon | Exposure to GLP-1 Analogue
Item
any exposure to exenatide (byetta® or bydureon™) or any glp-1 analog
boolean
C0332157 (UMLS CUI [1,1])
C0167117 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C1636686 (UMLS CUI [2,2])
C0332157 (UMLS CUI [3,1])
C3257792 (UMLS CUI [3,2])
C0332157 (UMLS CUI [4,1])
C3273809 (UMLS CUI [4,2])
Dipeptidyl Peptidase-4 Inhibitor
Item
any dpp-4 inhibitor within 3 months prior screening
boolean
C3537225 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video